Refine
Year of publication
Document Type
- Article (79)
- Preprint (17)
- Conference Proceeding (1)
Has Fulltext
- yes (97)
Is part of the Bibliography
- no (97)
Keywords
Institute
- Medizin (77)
- Informatik (21)
- Frankfurt Institute for Advanced Studies (FIAS) (19)
- Physik (19)
- Biochemie und Chemie (1)
- Biowissenschaften (1)
- Exzellenzcluster Herz-Lungen-System (1)
- Goethe-Zentrum für Wissenschaftliches Rechnen (G-CSC) (1)
- Institut für Ökologie, Evolution und Diversität (1)
- Pharmazie (1)
The first measurements of femtoscopic correlations with the particle pair combinations π±K0S in pp collisions at s√=13 TeV at the Large Hadron Collider (LHC) are reported by the ALICE experiment. Using the femtoscopic approach, it is shown that it is possible to study the elusive K∗0(700) particle that has been considered a tetraquark candidate for over forty years. Boson source parameters and final-state interaction parameters are extracted by fitting a model assuming a Gaussian source to the experimentally measured two-particle correlation functions. The final-state interaction is modeled through a resonant scattering amplitude, defined in terms of a mass and a coupling parameter, decaying into a π±K0S pair. The extracted mass and Breit-Wigner width, derived from the coupling parameter, of the final-state interaction are found to be consistent with previous measurements of the K∗0(700). The small value and increasing behavior of the correlation strength with increasing source size support the hypothesis that the K∗0(700) is a four-quark state, i.e. a tetraquark state. This latter trend is also confirmed via a simple geometric model that assumes a tetraquark structure of the K∗0(700) resonance.
The first measurements of femtoscopic correlations with the particle pair combinations π±K0S in pp collisions at s√=13 TeV at the Large Hadron Collider (LHC) are reported by the ALICE experiment. Using the femtoscopic approach, it is shown that it is possible to study the elusive K∗0(700) particle that has been considered a tetraquark candidate for over forty years. Boson source parameters and final-state interaction parameters are extracted by fitting a model assuming a Gaussian source to the experimentally measured two-particle correlation functions. The final-state interaction is modeled through a resonant scattering amplitude, defined in terms of a mass and a coupling parameter, decaying into a π±K0S pair. The extracted mass and Breit-Wigner width, derived from the coupling parameter, of the final-state interaction are found to be consistent with previous measurements of the K∗0(700). The small value and increasing behavior of the correlation strength with increasing source size support the hypothesis that the K∗0(700) is a four-quark state, i.e. a tetraquark state. This latter trend is also confirmed via a simple geometric model that assumes a tetraquark structure of the K∗0(700) resonance.
K+K− pairs may be produced in photonuclear collisions, either from the decays of photoproduced ϕ(1020) mesons, or directly as non-resonant K+K− pairs. Measurements of K+K− photoproduction probe the couplings between the ϕ(1020) and charged kaons with photons and nuclear targets. We present the first measurement of coherent photoproduction of K+K− pairs on lead ions in ultra-peripheral collisions using the ALICE detector, including the first investigation of direct K+K− production. There is significant K+K− production at low transverse momentum, consistent with coherent photoproduction on lead targets. In the mass range 1.1<MKK<1.4 GeV/c2 above the ϕ(1020) resonance, for rapidity |yKK|<0.8 and pT,KK<0.1 GeV/c, the measured coherent photoproduction cross section is dσ/dy = 3.37 ± 0.61 (stat.) ± 0.15 (syst.) mb. The centre-of-mass energy per nucleon of the photon-nucleus (Pb) system WγPb,n ranges from 33 to 188 GeV, far higher than previous measurements on heavy-nucleus targets. The cross section is larger than expected for ϕ(1020) photoproduction alone. The mass spectrum is fit to a cocktail consisting of ϕ(1020) decays, direct K+K− photoproduction, and interference between the two. The confidence regions for the amplitude and relative phase angle for direct K+K− photoproduction are presented.
Observation of abnormal suppression of f0(980) production in p–Pb collisions at √sNN = 5.02 TeV
(2023)
The dependence of f0(980) production on the final-state charged-particle multiplicity in p−Pb collisions at sNN−−−√=5.02 TeV is reported. The production of f0(980) is measured with the ALICE detector via the f0(980)→π+π− decay channel in a midrapidity region of −0.5<y<0. Particle yield ratios of f0(980) to π and K∗(892)0 are found to be decreasing with increasing charged-particle multiplicity. The magnitude of the suppression of the f0(980)/π and f0(980)/K∗(892)0 yield ratios is found to be dependent on the transverse momentum pT, suggesting different mechanisms responsible for the measured effects. Furthermore, the nuclear modification factor QpPb of f0(980) is measured in various multiplicity ranges. The QpPb shows a strong suppression of the f0(980) production in the pT region up to about 4 GeV/c. The results on the particle yield ratios and QpPb for f0(980) may help to understand the late hadronic phase in p−Pb collisions and the nature of the internal structure of f0(980) particle.
This Letter presents the measurement of near-side associated per-trigger yields, denoted ridge yields, from the analysis of angular correlations of charged hadrons in proton-proton collisions at s√ = 13 TeV. Long-range ridge yields are extracted for pairs of charged particles with a pseudorapidity difference of 1.4<|Δη|<1.8 and a transverse momentum of 1<pT<2 GeV/c, as a function of the charged-particle multiplicity measured at midrapidity. This study extends the measurements of the ridge yield to the low multiplicity region, where in hadronic collisions it is typically conjectured that a strongly-interacting medium is unlikely to be formed. The precision of the new results allows for the first direct quantitative comparison with the results obtained in e+e− collisions at s√ = 91 GeV, where initial-state effects such as pre-equilibrium dynamics and collision geometry are not expected to play a role. In the multiplicity range where the e+e− results have good precision, the measured ridge yields in pp collisions are substantially larger than the limits set in e+e− annihilations. Consequently, the findings presented in this Letter suggest that the processes involved in e+e− annihilations do not contribute significantly to the emergence of long-range correlations in pp collisions.
The femtoscopic study of pairs of identical pions is particularly suited to investigate the effective source function of particle emission, due to the resulting Bose-Einstein correlation signal. In small collision systems at the LHC, pp in particular, the majority of the pions are produced in resonance decays, which significantly affect the profile and size of the source. In this work, we explicitly model this effect in order to extract the primordial source in pp collisions at s√=13 TeV from charged π-π correlations measured by ALICE. We demonstrate that the assumption of a Gaussian primordial source is compatible with the data and that the effective source, resulting from modifications due to resonances, is approximately exponential, as found in previous measurements at the LHC. The universality of hadron emission in pp collisions is further investigated by applying the same methodology to characterize the primordial source of K-p pairs. The size of the primordial source is evaluated as a function of the transverse mass (mT) of the pairs, leading to the observation of a common scaling for both π-π and K-p, suggesting a collective effect. Further, the present results are compatible with the mT scaling of the p-p and p−Λ primordial source measured by ALICE in high multiplicity pp collisions, providing compelling evidence for the presence of a common emission source for all hadrons in small collision systems at the LHC. This will allow the determination of the source function for any hadron--hadron pairs with high precision, granting access to the properties of the possible final-state interaction among pairs of less abundantly produced hadrons, such as strange or charmed particles.
Background: In recent months, Omicron variants of SARS-CoV-2 have become dominant in many regions of the world, and case numbers with Omicron subvariants BA.1 and BA.2 continue to increase. Due to numerous mutations in the spike protein, the efficacy of currently available vaccines, which are based on Wuhan-Hu 1 isolate of SARS-CoV-2, is reduced, leading to breakthrough infections. Efficacy of monoclonal antibody therapy is also likely impaired.
Methods: In our in vitro study using A549-AT cells constitutively expressing ACE2 and TMPRSS2, we determined and compared the neutralizing capacity of vaccine-elicited sera, convalescent sera and monoclonal antibodies against authentic SARS-CoV-2 Omicron BA.1 and BA.2 compared with Delta.
Findings: Almost no neutralisation of Omicron BA.1 and BA.2 was observed using sera from individuals vaccinated with two doses 6 months earlier, regardless of the type of vaccine taken. Shortly after the booster dose, most sera from triple BNT162b2-vaccinated individuals were able to neutralise both Omicron variants. In line with waning antibody levels three months after the booster, only weak residual neutralisation was observed for BA.1 (26%, n = 34, 0 median NT50) and BA.2 (44%, n = 34, 0 median NT50). In addition, BA.1 but not BA.2 was resistant to the neutralising monoclonal antibodies casirivimab/imdevimab, while BA.2 exhibited almost a complete evasion from the neutralisation induced by sotrovimab.
Interpretation: Both SARS-CoV-2 Omicron subvariants BA.1 and BA.2 escape antibody-mediated neutralisation elicited by vaccination, previous infection with SARS-CoV-2, and monoclonal antibodies. Waning immunity renders the majority of tested sera obtained three months after booster vaccination negative in BA.1 and BA.2 neutralisation. Omicron subvariant specific resistance to the monoclonal antibodies casirivimab/imdevimab and sotrovimab emphasizes the importance of genotype-surveillance and guided application.
Funding: This study was supported in part by the Goethe-Corona-Fund of the Goethe University Frankfurt (M.W.) and the Federal Ministry of Education and Research (COVIDready; grant 02WRS1621C (M.W.).
Background: Postoperative complication rates using 3D visualization are rarely reported. The primary aim of our study is to detect a possible advantage of using 3D on postoperative complication rates in a real-world setting.
Method: With a sample size calculation for a medium effect size difference that 3D reduces significantly postoperative complications, data of 287 patients with 3D visualization and 832 with 2D procedure were screened. The groups underwent an exact propensity score-matching to be comparable. Comprehensive complication index (CCI) for every procedure was calculated and Operation Time was determined.
Results: Including 1078 patients in the study, 213 exact propensity score-matched pairs could finally be established. Concerning overall CCI (3D: 5.70 ± 13.63 vs. 2D: 3.37 ± 9.89; p = 0.076) and operation time (3D: 103.98 ± 93.26 min vs. 2D: 88.60 ±6 9.32 min; p = 0.2569) there was no significant difference between the groups.
Conclusion: Our study shows no advantage of 3D over 2D laparoscopy regarding postoperative complications in a real-world setting, the second endpoint operation time, too, was not influenced by 3D overall.
Keywords: 3D laparoscopy; Comprehensive complication index; Propensity score matching
Introduction Patients undergoing heart valve surgery are predominantly transferred postoperatively to the intensive care unit (ICU) under continuous sedation. Volatile anaesthetics are an increasingly used treatment alternative to intravenous substances in the ICU. As subject to inhalational uptake and elimination, the resulting pharmacological benefits have been repeatedly demonstrated. Therefore, volatile anaesthetics appear suitable to meet the growing demands of fast-track cardiac surgery. However, their use requires special preparation at the bedside and trained medical and nursing staff, which might limit the pharmacological benefits. The aim of our work is to assess whether the temporal advantages of recovery under volatile sedation outweigh the higher effort of special preparation.
Methods and analysis The study is designed to evaluate the differences between intravenous sedatives (n=48) and volatile sedatives (n=48) in continued intensive care sedation. This study will be conducted as a prospective, randomised, controlled, single-blinded, monocentre trial at a German university hospital in consenting adult patients undergoing heart valve surgery at a university hospital. This observational study will examine the necessary preparation time, staff consultation and overall feasibility of the chosen sedation method. For this purpose, the continuation of sedation in the ICU with volatile sedatives is considered as one study arm and with intravenous sedatives as the comparison group. Due to rapid elimination and quick awakening after the termination of sedation, closer consultation between the attending physician and the ICU nursing staff is required, in addition to a prolonged setup time. Study analysis will include the required setup time, time from admission to extubation as primary outcome and neurocognitive assessability. In addition, possible operation-specific (blood loss, complications), treatment parameters (catecholamine dosages, lung function) and laboratory results (acute kidney injury, acid base balance (lactataemia), liver failure) as influencing factors will be collected. The study-relevant data will be extracted from the continuous digital records of the patient data management system after the patient has been discharged from the ICU. For statistical evaluation, 95% CIs will be calculated for the median time to extubation and neurocognitive assessability, and the association will be assessed with a Cox regression model. In addition, secondary binary outcome measures will be evaluated using Fisher’s exact tests. Further descriptive and exploratory statistical analyses are also planned.
Ethics and dissemination The study was approved by the Institutional Ethics Board of the University of Frankfurt, Germany (#20-1050). Informed consent of all individual patients will be obtained before randomisation. Results will be disseminated via publication in peer-reviewed journals.
Objectives: Regarding reactogenicity and immunogenicity, heterologous COVID-19 vaccination regimens are considered as an alternative to conventional immunization schemes.
Methods: Individuals receiving either heterologous (ChAdOx1-S [AstraZeneca, Cambridge, UK]/BNT162b2 [Pfizer-BioNTech, Mainz, Germany]; n = 306) or homologous (messenger RNA [mRNA]-1273 [Moderna, Cambridge, Massachusetts, USA]; n = 139) vaccination were asked to participate when receiving their second dose. Reactogenicity was assessed after 1 month, immunogenicity after 1, 3, and/or 6 months, including a third dose, through SARS-CoV-2 antispike immunoglobulin G, surrogate virus neutralization test, and a plaque reduction neutralization test against the Delta (B.1.167.2) and Omicron (B.1.1.529; BA.1) variants of concern.
Results: The overall reactogenicity was lower after heterologous vaccination. In both cohorts, SARS-CoV-2 antispike immunoglobulin G concentrations waned over time with the heterologous vaccination demonstrating higher neutralizing activity than homologous mRNA vaccination after 3 months to low neutralizing levels in the Delta plaque reduction neutralization test after 6 months. At this point, 3.2% of the heterologous and 11.4% of the homologous cohort yielded low neutralizing activity against Omicron. After a third dose of an mRNA vaccine, ≥99% of vaccinees demonstrated positive neutralizing activity against Delta. Depending on the vaccination scheme and against Omicron, 60% to 87.5% of vaccinees demonstrated positive neutralizing activity.
Conclusion: ChAdOx1-S/BNT162b2 vaccination demonstrated an acceptable reactogenicity and immunogenicity profile. A third dose of an mRNA vaccine is necessary to maintain neutralizing activity against SARS-CoV-2. However, variants of concern-adapted versions of the vaccines would be desirable.